Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3471851 in Moderate to Severe Active Ulcerative Colitis – Induction
CTR20212231Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rezpegaldesleukin in autoimmune colitis, sponsored by Eli Lilly and Company. Started Sep 2021; status: terminated.
02
Drugs
rezpegaldesleukin
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20212231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212231.